)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
MediWound
MediWound (MDWD) investor relations material
MediWound Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Advanced EscharEx’s Phase III VALUE trial and expanded NexoBrid development and manufacturing capacity; NexoBrid sales remain supply-constrained.
Q3 revenue declined year over year as U.S. government development-services revenue fell; higher VALUE investment contributed to increased losses.
A November public offering and warrant exercises added financing, while anticipated 2026 revenue remains exposed to uncertain U.S.-facility funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MediWound
- NexoBrid revenue and EscharEx’s chronic-wound pipeline anchor growth targets.MDWD
Company presentation - VALUE results and expanded NexoBrid capacity are the key upcoming milestones.MDWDH.C. Wainwright 28th Annual Global Investment Conference
- VALUE phase III advances, NexoBrid hits record U.S. sales, 2026 guidance reaffirmed.MDWDQ2 2026
- Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds.MDWDCorporate presentation
- Enzymatic therapies drive strong growth, with robust data and major market expansion ahead.MDWDCorporate presentation
- Q1 revenue fell but margin improved; BARDA and NexoBrid drive strong H2 2026 outlook.MDWDQ1 2026
- 2025 revenue fell to $17M, but gross margin and cash reserves improved.MDWDQ4 2025
- Q3 revenue up 23% YoY, net loss narrowed, $30M equity raised, and EscharEx peak sales at $831M.MDWDQ3 2025
- Q1 revenue was $4M, gross margin rose to 19%, and NexoBrid U.S. sales reached record highs.MDWDQ1 2025
Next MediWound earnings date
Q4 20265 Mar, 2027
MediWound
Next MediWound earnings date
Q4 20265 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
MediWound Ltd. specializes in the development, manufacture, and commercialization of innovative therapies for tissue repair and regeneration. The company focuses primarily on enzymatic debridement solutions for the treatment of severe burns, chronic wounds, and other hard-to-heal injuries. MediWound's proprietary technologies are designed to improve the healing process by selectively removing dead or damaged tissue without harming surrounding healthy tissue. The company serves healthcare providers, hospitals, and wound care centers globally, aiming to enhance patient outcomes and reduce treatment costs. MediWound is headquartered in Yavne, Israel, and its shares are listed on the NASDAQ.